Browsing Tag
UroGen Pharma Ltd.
4 posts
UroGen takes $7m IntraGel stake as local oncology pipeline expands beyond bladder cancer
UroGen Pharma is investing up to $7 million in IntraGel Therapeutics while securing options on TumoCure and as many as three additional oncology programs built around sustained local drug delivery.
What the latest UTOPIA trial data reveal about UGN-103’s competitive position in LG-IR-NMIBC
UroGen Pharma Ltd.’s UGN-103 posted strong Phase 3 bladder cancer durability data. Discover what it means for NMIBC competition and growth.
Hope for bladder cancer patients? UroGen’s UGN-301 shows strong safety and clinical activity in early trial
Find out how UroGen Pharma’s UGN-301 is offering new hope for bladder cancer patients with promising Phase 1 trial results. Read the latest developments here!
Breakthrough for recurrent bladder cancer: UroGen’s UGN-102 achieves 80.6% 18-month complete response in phase 3 trial
Discover how UroGen Pharma’s UGN-102 could transform bladder cancer treatment with durable results; find out what the Phase 3 ENVISION trial reveals!